World's Best Scientists 2026 revealed!

D-Index & Metrics

Microbiology

D-Index
58
Citations
10393
World Ranking
3475
National Ranking
1372

Paul M. Sondel publication distribution in Microbiology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Microbiology in 2026. The highlighted bar marks where Paul M. Sondel sits on this spectrum.

55–64 publications: 8 scientists 65–74 publications: 29 scientists 75–84 publications: 55 scientists 85–94 publications: 112 scientists 95–104 publications: 137 scientists 105–114 publications: 190 scientists 115–124 publications: 235 scientists 125–134 publications: 234 scientists 135–144 publications: 288 scientists 145–154 publications: 264 scientists 155–164 publications: 264 scientists 165–174 publications: 253 scientists 175–184 publications: 276 scientists 185–194 publications: 190 scientists 195–204 publications: 233 scientists 205–214 publications: 207 scientists 215–224 publications: 198 scientists 225–234 publications: 155 scientists 235–244 publications: 161 scientists 245–254 publications: 160 scientists 255–264 publications: 146 scientists 265–274 publications: 139 scientists 275–284 publications: 148 scientists 285–294 publications: 115 scientists 295–304 publications: 96 scientists 305–314 publications: 88 scientists 315–324 publications: 106 scientists 325–334 publications: 65 scientists 335–344 publications: 76 scientists 345–354 publications: 64 scientists 355–364 publications: 62 scientists 365–374 publications: 65 scientists 375–384 publications: 61 scientists 385–394 publications: 34 scientists 395–404 publications: 44 scientists 405–414 publications: 36 scientists 415–424 publications: 35 scientists 425–434 publications: 29 scientists 435–444 publications: 33 scientists 445–454 publications: 34 scientists 455–464 publications: 25 scientists 465–474 publications: 26 scientists 475–484 publications: 20 scientists 485–494 publications: 19 scientists 495–504 publications: 16 scientists 505–514 publications: 17 scientists 515–524 publications: 23 scientists 525–534 publications: 14 scientists 535–544 publications: 14 scientists 545–554 publications: 18 scientists 555–564 publications: 12 scientists 565–574 publications: 7 scientists 575–584 publications: 9 scientists 585–594 publications: 9 scientists 595–604 publications: 9 scientists 605–614 publications: 7 scientists 615–624 publications: 9 scientists 625–634 publications: 7 scientists 635–644 publications: 4 scientists 645–654 publications: 5 scientists 655–664 publications: 6 scientists 665–674 publications: 7 scientists 675–678 publications: 3 scientists 679+ publications: 99 scientists
55 publications 679+

This scientist: 323 publications — 81st percentile

81% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 679 publications or more.

Paul M. Sondel D-index placement in Microbiology in 2026

The chart shows the D-index (discipline H-index) distribution of Microbiology scientists ranked by Research.com in 2026. The highlighted bar marks where Paul M. Sondel sits on this spectrum.

40 D-Index: 30 scientists 41 D-Index: 86 scientists 42 D-Index: 90 scientists 43 D-Index: 117 scientists 44 D-Index: 122 scientists 45 D-Index: 123 scientists 46 D-Index: 108 scientists 47 D-Index: 110 scientists 48 D-Index: 106 scientists 49 D-Index: 109 scientists 50 D-Index: 129 scientists 51 D-Index: 111 scientists 52 D-Index: 116 scientists 53 D-Index: 127 scientists 54 D-Index: 134 scientists 55 D-Index: 134 scientists 56 D-Index: 111 scientists 57 D-Index: 136 scientists 58 D-Index: 162 scientists 59 D-Index: 151 scientists 60 D-Index: 139 scientists 61 D-Index: 122 scientists 62 D-Index: 126 scientists 63 D-Index: 144 scientists 64 D-Index: 109 scientists 65 D-Index: 103 scientists 66 D-Index: 124 scientists 67 D-Index: 112 scientists 68 D-Index: 103 scientists 69 D-Index: 131 scientists 70 D-Index: 93 scientists 71 D-Index: 93 scientists 72 D-Index: 96 scientists 73 D-Index: 92 scientists 74 D-Index: 80 scientists 75 D-Index: 66 scientists 76 D-Index: 87 scientists 77 D-Index: 60 scientists 78 D-Index: 73 scientists 79 D-Index: 59 scientists 80 D-Index: 57 scientists 81 D-Index: 55 scientists 82 D-Index: 47 scientists 83 D-Index: 77 scientists 84 D-Index: 50 scientists 85 D-Index: 45 scientists 86 D-Index: 42 scientists 87 D-Index: 41 scientists 88 D-Index: 32 scientists 89 D-Index: 38 scientists 90 D-Index: 35 scientists 91 D-Index: 34 scientists 92 D-Index: 27 scientists 93 D-Index: 26 scientists 94 D-Index: 33 scientists 95 D-Index: 22 scientists 96 D-Index: 37 scientists 97 D-Index: 22 scientists 98 D-Index: 21 scientists 99 D-Index: 22 scientists 100 D-Index: 30 scientists 101 D-Index: 16 scientists 102 D-Index: 20 scientists 103 D-Index: 17 scientists 104 D-Index: 19 scientists 105 D-Index: 16 scientists 106 D-Index: 19 scientists 107 D-Index: 18 scientists 108 D-Index: 14 scientists 109 D-Index: 10 scientists 110 D-Index: 9 scientists 111 D-Index: 7 scientists 112 D-Index: 11 scientists 113 D-Index: 6 scientists 114 D-Index: 15 scientists 115 D-Index: 10 scientists 116 D-Index: 12 scientists 117 D-Index: 7 scientists 118 D-Index: 10 scientists 119 D-Index: 10 scientists 120 D-Index: 11 scientists 121 D-Index: 2 scientists 122 D-Index: 7 scientists 123 D-Index: 12 scientists 124 D-Index: 5 scientists 125 D-Index: 9 scientists 126 D-Index: 6 scientists 127+ D-Index: 95 scientists
40 D-Index 127+

This scientist: 58 D-Index — 39th percentile

39% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 127 D-Index or more.

Overview

Paul M. Sondel is affiliated with the University of Wisconsin-Madison in the United States. Their research spans multiple disciplines with a focus on medicine, biochemistry, genetics and molecular biology, and immunology and microbiology. The main subfields of their work include oncology, immunology, neurology, molecular biology, and radiology, nuclear medicine and imaging.

The scientist's research covers a range of topics that emphasize neuroblastoma research and treatments, immunotherapy and immune responses, cancer immunotherapy and biomarkers, CAR-T cell therapy research, cancer related to hypoxia and metabolism, monoclonal and polyclonal antibodies research, and broader cancer research and treatments.

Some of the recent publications by Paul M. Sondel include:

  • Low-dose targeted radionuclide therapy renders immunologically cold tumors responsive to immune checkpoint blockade (2021), published in Science Translational Medicine
  • Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032 (2021), published in Clinical Cancer Research
  • Irinotecan, Temozolomide, and Dinutuximab With GM-CSF in Children With Refractory or Relapsed Neuroblastoma: A Report From the Children's Oncology Group (2020), published in Journal of Clinical Oncology
  • Depletion of tumor associated macrophages enhances local and systemic platelet-mediated anti-PD-1 delivery for post-surgery tumor recurrence treatment (2022), published in Nature Communications
  • Immunotherapy of Neuroblastoma: Facts and Hopes (2022), published in Clinical Cancer Research

Frequent co-authors include:

  • Amy K. Erbe
  • Alexander L. Rakhmilevich
  • Zachary S. Morris
  • Arika S. Feils
  • Anna Hoefges

The main publication venues for this researcher include:

  • Regular and Young Investigator Award Abstracts
  • Journal for ImmunoTherapy of Cancer
  • Cancer Research
  • Journal of Clinical Oncology
  • bioRxiv (Cold Spring Harbor Laboratory)

Best Publications

  • Recognition by human V gamma 9/V delta 2 T cells of a GroEL homolog on Daudi Burkitt's lymphoma cells

    Paul Fisch;Miroslav Malkovsky;Susan Kovats;Els Sturm

  • Homozygous deletions that simultaneously eliminate expressions of class I and class II antigens of EBV-transformed B-lymphoblastoid cells. I. Reduced proliferative responses of autologous and allogeneic T cells to mutant cells that have decreased expression of class II antigens

    Robert DeMars;Robert DeMars;Cecile C Chang;Cecile C Chang;Stephen Shaw;Stephen Shaw;Pamela J Reitnauer;Pamela J Reitnauer

  • Phase I Study of Chimeric Human/Murine Anti–Ganglioside GD2 Monoclonal Antibody (ch14.18) With Granulocyte-Macrophage Colony-Stimulating Factor in Children With Neuroblastoma Immediately After Hematopoietic Stem-Cell Transplantation: A Children’s Cancer Group Study

    M. Fevzi Ozkaynak;Paul M. Sondel;Mark D. Krailo;Jacek Gan

  • Interferon-induced indoleamine 2,3-dioxygenase activity in human mononuclear phagocytes.

    Joseph M. Carlin;Ernest C. Borden;Paul M. Sondel;Gerald I. Byrne

  • Implications of interferon-induced tryptophan catabolism in cancer, auto-immune diseases and AIDS.

    R. R. Brown;Y. Ozaki;S. P. Datta;Ernest C Borden

  • A Phase I Clinical Trial of the hu14.18-IL2 (EMD 273063) as a Treatment for Children with Refractory or Recurrent Neuroblastoma and Melanoma: a Study of the Children’s Oncology Group

    Kaci L. Osenga;Jacquelyn A. Hank;Mark R. Albertini;Jacek Gan

  • Phase I Clinical Trial of the Immunocytokine EMD 273063 in Melanoma Patients

    David M. King;Mark R. Albertini;Heidi Schalch;Jacquelyn A. Hank

  • Low-dose targeted radionuclide therapy renders immunologically cold tumors responsive to immune checkpoint blockade

    Ravi B. Patel;Reinier Hernandez;Peter Carlson;Joseph Grudzinski

  • Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032.

    Alice L. Yu;Alice L. Yu;Andrew L. Gilman;M. Fevzi Ozkaynak;Arlene Naranjo

  • Genotypes of NK Cell KIR Receptors, Their Ligands, and Fcγ Receptors in the Response of Neuroblastoma Patients to Hu14.18-IL2 Immunotherapy

    David C. Delgado;Jacquelyn A. Hank;Jill Kolesar;David Lorentzen

  • Repetitive weekly cycles of recombinant human interleukin-2: responses of renal carcinoma with acceptable toxicity.

    Jeff A. Sosman;Peter C. Kohler;Jacquelyn Hank;Karen H. Moore

  • A multigene family on human chromosome 12 encodes natural killer-cell lectins.

    Toshio Yabe;Cynthia McSherry;Fritz H. Bach;Paul Fisch

  • Irinotecan, Temozolomide, and Dinutuximab With GM-CSF in Children With Refractory or Relapsed Neuroblastoma: A Report From the Children's Oncology Group.

    Rajen Mody;Alice L Yu;Alice L Yu;Arlene Naranjo;Fan F Zhang

  • Anti-CD40 antibody induces antitumor and antimetastatic effects: the role of NK cells.

    Joel G. Turner;Alexander L. Rakhmilevich;Lyudmila Burdelya;Zane Neal

  • Lymphokines and cytokines as cancer treatment. Immunotherapy realized.

    Ernest C. Borden;Paul M. Sondel

  • Destruction of autologous human lymphocytes by interleukin 2-activated cytotoxic cells.

    P M Sondel;J A Hank;P C Kohler;B P Chen

  • Activation of human effector cells by a tumor reactive recombinant anti-ganglioside GD2 interleukin-2 fusion protein (ch14.18-IL2).

    Jacquelyn A. Hank;Jean E. Surfus;Jacek Gan;Peter Jaeger

  • CD40 Ligation Activates Murine Macrophages via an IFN-γ-Dependent Mechanism Resulting in Tumor Cell Destruction In Vitro

    Ilia N. Buhtoiarov;Hillary Lum;Gideon Berke;Donna M. Paulnock

  • Human V gamma 9-V delta 2 T cell receptor-gamma delta lymphocytes show specificity to Daudi Burkitt's lymphoma cells.

    E. Sturm;E. Braakman;P. Fisch;R. J. Vreugdenhil

  • Evaluating natural killer cell cytotoxicity against solid tumors using a microfluidic model.

    Jose M. Ayuso;Jose M. Ayuso;Regan Truttschel;Max M. Gong;Mouhita Humayun

  • Antigenic requirements for triggering of cytotoxic T lymphocytes.

    Fritz H. Bach;Catherine Grillot-Courvalin;Oded J. Kuperman;Hans W. Sollinger

Frequent Co-Authors

Jacquelyn A. Hank
Jacquelyn A. Hank University of Wisconsin–Madison
Stephen D. Gillies
Stephen D. Gillies MSD (United States)
Jeffrey A. Sosman
Jeffrey A. Sosman Northwestern University
Ralph A. Reisfeld
Ralph A. Reisfeld Scripps Research Institute
Alice L. Yu
Alice L. Yu University of California, San Diego
Wendy B. London
Wendy B. London Harvard University
John M. Maris
John M. Maris Children's Hospital of Philadelphia
Robert DeMars
Robert DeMars University of Wisconsin–Madison
Joan H. Schiller
Joan H. Schiller University of Virginia
Paul M. Harari
Paul M. Harari University of Wisconsin–Madison

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring online degrees related to microbiology opens up diverse career pathways. For instance, pursuing healthcare-focused programs can lead to roles like a child life specialist, a profession where understanding biology and human development is crucial. Interested students often research how much do child life specialists make to gauge financial prospects in the field.

For those with unique backgrounds, including individuals with previous convictions, it's encouraging to note the availability of options like the best degrees for felons. Many online programs provide pathways to careers in healthcare and science that are accessible and lead to rewarding opportunities.

Another promising direction is becoming a functional medicine NP, which combines traditional microbiology knowledge with patient-centered care. This role is growing in demand as holistic health approaches become more mainstream.

For those drawn to the administrative or coding side of healthcare, obtaining a CPC certification can be a smart move. Understanding the cpc certification salary and career paths helps prospective students evaluate the benefits of this certification, especially when paired with a science background.

Choosing the right online degree linked to microbiology can open multiple doors in the healthcare and science sectors, each with unique benefits and career growth potential.

Best Scientists Citing Paul M. Sondel

Trending Scientists